{
  "folder": "IC-074",
  "content": "{{knowledge objective\n|Identifiant=OIC-074-21-A\n|Item_parent=Prescription and monitoring of psychotropic drugs (see item 330)\n|Item_parent_short=Prescription and monitoring of psychotropic drugs (see item 330)\n|Rank=A\n|Title=Thymoregulators: knowing the main classes and molecules\n|Description=None\n|Rubric=Definition\n|Contributors=\n|Order=21}}\nThymoregulators'' are ''psychotropic'' drugs whose main clinical action is to '''reduce the frequency''', '''duration''' and '''intensity''' of '''thymic episodes''' (manic and depressive).\n\nThey represent a fairly restricted pharmacological class which includes :\n\n* lithium salts,\n* anticonvulsant thymoregulators: valpromide, sodium divalproate, carbamazepine, lamotrigine, etc.",
  "question": {
    "question": "Thymoregulators primarily act to reduce the frequency, duration, and intensity of thymic episodes by which mechanism?",
    "option_a": "Increasing the release of neurotransmitters such as serotonin and dopamine",
    "option_b": "Blocking the reabsorption of neurotransmitters such as norepinephrine and GABA",
    "option_c": "Inhibiting the activity of the hypothalamic-pituitary-adrenal axis",
    "option_d": "Stimulating the release of cortisol and other glucocorticoids"
  }
}